• J de A Claro, J E de Aboim, M Maríngolo, E Andrade, W Aguiar, M Nogueira, A Nardozza Júnior, and M Srougi.
• Urology Department, Universidade Federal de São Paulo/Escola Paulista de Medicina, São Paulo, Brazil. joaquimclaro@hotmail.com
• Sao Paulo Med J. 2001 Jul 5; 119 (4): 135137135-7.

ContextDespite the recent improvements in performing radical retropubic prostatectomy that have led to a considerable decrease in the complication rate, erectile dysfunction still represents a major problem. Moreover, less invasive treatment options that are emerging for erectile dysfunction have not shown satisfactory results in managing these patients.ObjectiveTo study the efficacy and side effects of self-injection therapy in the treatment of men who had become impotent after undergoing radical prostatectomy due to prostate cancer, over a study period of 96 months.DesignObservational study.SettingUniversity Referral Center.Participants168 patients with erectile dysfunction, aged 43 to 78 years old, who underwent radical retropubic prostatectomy due to localized prostate cancer.ProceduresThe patients were treated with self-injection therapy using papaverine, phentolamine and prostaglandin E1, at home.ResultsThis study showed an acceptable 94.6% success rate, with no life-threatening complications. In addition to this, our series presented a 13.1% cure rate with this therapy.ConclusionSelf-injection therapy with papaverine, phentolamine and prostaglandin E1 is effective and safe in the treatment of erectile dysfunction after radical prostatectomy.

22 keywords...

hide…